Vismodegib has antitumor activity in basal cell carcinoma

Share this article:
Vismodegib Has Antitumor Activity in Basal Cell Carcinoma
Vismodegib Has Antitumor Activity in Basal Cell Carcinoma

(HealthDay News) -- A small-molecule inhibitor of the hedgehog pathway, vismodegib, is associated with tumor response in patients with metastatic or locally advanced basal cell carcinoma (BCC); and vismodegib is efficacious for preventing and treating BCCs in patients with basal cell nevus syndrome, according to two studies published in the June 7 issue of the New England Journal of Medicine.

Aleksandar Sekulic, M.D., Ph.D., from the Mayo Clinic in Scottsdale, Ariz., and colleagues enrolled 33 patients with metastatic BCC and 63 with locally advanced BCC in a multicenter, international, two-cohort, nonrandomized study. Participants received 150 mg oral vismodegib daily. The researchers found that the objective response rate was 30 percent in the patients with metastatic BCC and 43 percent in those with locally advanced BCC, with complete responses in 21 percent of patients in the cohort with locally advanced BCC. In both cohorts, the median duration of response was 7.6 months.

Jean Y. Tang, M.D., Ph.D., from the Children's Hospital of Oakland Research Institute in California, and colleagues conducted a randomized, double-blind, placebo-controlled trial of vismodegib involving 41 patients with basal cell nevus syndrome. After a mean follow-up of eight months, the researchers found that the per-patient rate of new surgically eligible BCCs was significantly lower with vismodegib than placebo. The size of existing clinically significant BCCs was also significantly smaller with vismodegib. Due to adverse events, 54 percent of patients receiving the drug discontinued vismodegib treatment.

"Our findings confirm the essential role of the hedgehog pathway in basal cell carcinomas and indicate that vismodegib is efficacious in preventing and treating basal cell carcinomas in patients with the basal cell nevus syndrome," Tang and colleagues conclude.

Authors from both studies disclosed financial ties to pharmaceutical companies, including Genentech, which funded the studies and developed vismodegib.

Full Text - Sekulic (subscription or payment may be required)
Full Text - Tang (subscription or payment may be required)
Editorial (subscription or payment may be required)

Share this article:
You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs